Diabetes news and diabetes widget

An increasing number of type 2 diabetes patients in the U.S. are being treated by a progressively complex mix of therapies, according to a study featured in Archives of Internal medicine, a JAMA/Archives journal. The report is the first to be published by members of the health Services Research Network (HSRN), a consortium of leading U.S. academicians that conducts independent research using IMS health's evidence-based information to address key healthcare issues.

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and development, and the Joslin diabetes Center, the world's preeminent diabetes research and clinical care organization, today announced a collaboration to carry out human clinical and animal studies in the area of insulin resistance and type 2 diabetes. This collaboration agreement includes a series of studies to be conducted using Metabolon's biochemical profiling technology.

To address the growing epidemic of type 2 diabetes affecting American Indian youth, researchers from UNLV were part of a national collaboration with three federal agencies and eight tribal colleges to develop "Health is Life in Balance" - an innovative K-12 diabetes curriculum for tribal schools and schools with large American Indian/Alaska Native populations. The curriculum blends the science of diabetes with Native cultural teachings.

A drug based on a chemical found in garlic can treat diabetes types I and II when taken as a tablet, a study in the new Royal Society of Chemistry journal Metallomics says. When Hiromu Sakurai and colleagues from the Suzuka University of Medical Science, Japan, gave the drug orally to type I diabetic mice, they found it reduced blood glucose levels.

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announced the first data of a new Phase I clinical trials of GFT505, a drug candidate for the treatment of atherogenic dyslipidemia associated with pre-diabetes and diabetes (GFT505-1084 studies).

HIV-positive people receiving treatment for the virus might be at an increased risk of developing heart disease and type 2 diabetes because some antiretroviral drugs can cause fat on the arms, legs, face and buttocks to move to the stomach, researchers at Australia's Garvan Institute said Monday, the

VeriChip Corporation ("VeriChip") (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGNT chemistry platform can be applied to the development of selective binding products, announced today that a significant milestone has been achieved toward the development of an in vivo glucose-sensing RFID microchip.

Reuters - New research shows that among the mental abilities that are affected by type 2 diabetes, the speed at which the brain processes information appears to be the most severely impaired, particularly in patients with undiagnosed disease.

Title: Genetic Screening May ID diabetes RiskCategory: health newscreated: 11/20/2008Last Editorial review: 11/20/2008